论文部分内容阅读
目的评估伊斑膦酸钠对前列腺癌骨转移患者药物去势治疗后骨密度的影响。方法晚期前列腺癌患者30例,给予最大雄激素阻断治疗,随机分为两组,治疗组15例给予伊斑膦酸钠治疗(4 mg,每月一次,静脉滴注),对照组15例未给予伊斑膦酸钠治疗。两组患者去势治疗前骨密度指标差异无统计学意义(P>0.05);观察去势治疗后3、6和12月时的骨密度变化。结果治疗3月时,两组患者骨密度指标均有下降,但差异无统计学意义(P>0.05);6月时,治疗组骨密度增加,对照组骨密度下降,差异仍无统计学意义(P>0.05);12月时,骨密度差异有统计学意义(P=0.001)。结论前列腺癌患者接受药物去势治疗后12月时其骨密度较治疗前明显降低,而伊斑膦酸钠可减缓前列腺癌患者接受药物去势治疗后骨密度下降,减少骨丢失。
Objective To evaluate the effect of ibuprofen sodium on bone mineral density (BMD) in patients with bone metastases from prostate cancer after drug exfoliation treatment. Methods Thirty patients with advanced prostate cancer were treated with maximal androgen blockade, and were randomly divided into two groups. Fifteen patients in the treatment group were treated with ibuprofen sodium (4 mg once a month by intravenous drip) and 15 patients in the control group No treatment with ibuprofen was given. There was no significant difference in BMD between the two groups before castration (P> 0.05). The changes of BMD at 3, 6 and 12 months after castration were observed. Results At 3 months of treatment, the BMD of both groups decreased, but the difference was not statistically significant (P> 0.05). At 6 months, the BMD of the treatment group increased and the BMD of the control group decreased, the difference was not statistically significant (P> 0.05). There was a significant difference in BMD between December and December (P = 0.001). Conclusion BMD in patients with prostate cancer was significantly lower than that before treatment after 12 months of treatment. However, ibuprofen reduced the BMD and reduced bone loss in prostate cancer patients treated with drug castration.